CF
AUPH icon

Corebridge Financial’s Aurinia Pharmaceuticals AUPH Stock Holding History

Corebridge Financial’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-65,769
Closed -$529K – 259
2025
Q1 		$529K Sell
65,769
-975
-1% -$7.9K ﹤0.01% 1563
2024
Q4 		$599K Sell
66,744
-5,038
-7% -$41.1K ﹤0.01% 1578
2024
Q3 		$526K Sell
71,782
-5,458
-7% -$33.8K ﹤0.01% 1711
2024
Q2 		$441K Buy
+77,240
New +$407K ﹤0.01% 1757

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Corebridge Financial's AUPH Position: Q2 2025 in Review

Corebridge Financial sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 65,769 shares — an estimated $529K sold.

Corebridge Financial first reported a position in AUPH in Q2 2024 and held it in 4 quarters. The position peaked at $599K in Q4 2024. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Corebridge Financial reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 65,769 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $529K.
  • Corebridge Financial first reported a position in Aurinia Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Aurinia Pharmaceuticals position peaked at $599K in Q4 2024.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.